デフォルト表紙
市場調査レポート
商品コード
1673034

急性腎障害治療市場:タイプ別、治療別、流通チャネル別、地域別

Acute Kidney Injury Treatment Market, By Type, By Treatment, By Distribution Channel, By Geography


出版日
ページ情報
英文 156 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
急性腎障害治療市場:タイプ別、治療別、流通チャネル別、地域別
出版日: 2025年02月19日
発行: Coherent Market Insights
ページ情報: 英文 156 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の急性腎障害治療市場は、2025年には19億6,000万米ドルと推定され、2032年には34億3,000万米ドルに達すると予測され、2025~2032年にかけてCAGR8.3%で成長する見込みです。

レポート範囲 レポート詳細
基準年 2024年 2025年の市場規模 19億6,000万米ドル
実績データ 2020~2024年 予測期間 2025~2032年
予測期間:2025~2032年のCAGR 8.30% 2032年の金額予測 34億3,000万米ドル
図.急性腎障害治療市場シェア(%)、2025年地域別
Acute Kidney Injury Treatment Market-IMG1

急性腎障害(AKI)とは、腎臓の急激な機能低下により、通常は腎臓で除去されるはずの老廃物が血液中に蓄積することを指します。さらなる腎障害や腎不全を防ぐためには、迅速な医療処置が必要な重篤な状態です。世界の急性腎障害治療市場の成長を牽引しているのは、AKIのリスクを高める糖尿病や高血圧などの併存疾患の有病率の上昇です。さらに、新規薬剤や治療アプローチの開発により、患者の治療選択肢が広がっています。しかし、AKIに関する人々や医療プロバイダーの認識不足が市場成長の妨げとなる可能性があります。

市場力学

世界の急性腎障害治療市場の成長を牽引しているのは、加齢に伴う腎機能の低下によりAKIに罹患しやすい高齢者の増加です。国連によると、65歳以上の高齢者数は2050年までに15億人以上に達すると予測されています。ライフスタイルの変化による慢性腎臓病の有病率の増加も、市場成長の原動力となります。しかし、腎代替療法に伴う高コストが普及を制限する可能性があります。AKIの早期診断に関する認識不足は市場成長の妨げとなる可能性があります。AKIを早期発見するためのバイオマーカーの開発は、市場開拓企業にとってこのセグメントでの事業拡大の好機となります。体液状態のリアルタイムモニタリングは、リアルタイムでカスタマイズ型ケアを記載しています。デジタルヘルスソリューションは、遠隔患者管理にも役立ちます。

本調査の主要特徴

本レポートでは、世界の急性腎障害治療市場を詳細に分析し、2024年を基準年とした予測期間(2025~2032年)の市場規模(10億米ドル)と複合年間成長率(CAGR%)を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の急性腎障害治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

本調査の対象となる主要企業には、Fresenius Medical Care AG & Co.KGaA、Baxter、Angion Biomedica Corp、AM-Pharma、Quark Pharmaceuticals, Inc.などがあります。

このレポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の急性腎障害治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。

利害関係者は、世界の急性腎障害治療市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 影響分析
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • ポーター分析
  • 合併と買収のシナリオ

第4章 世界の急性腎障害治療市場、タイプ別、2020~2032年(10億米ドル)

  • イントロダクション
  • 腎前性急性腎障害
  • 内因性腎急性腎障害
  • 腎後性急性腎障害

第5章 世界の急性腎障害治療市場、治療別、2020~2032年(10億米ドル)

  • イントロダクション
  • 治療
  • 薬剤

第6章 世界の急性腎障害治療市場、流通チャネル別、2020~2032年(10億米ドル)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の急性腎障害治療市場、地域別、2020~2032年(10億米ドル)

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第8章 競合情勢

  • Angion Biomedica Corp.
  • AM-Pharma
  • Quark Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Braun Melsungen AG
  • Asahi Kasei Medical Co., Ltd.
  • LG Chem
  • Kringle Pharma, Inc.
  • AstraZeneca
  • Amgen Inc.
  • Gilead Sciences
  • Roche
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG
  • AbbVie Inc.

第9章 アナリストの推奨事項

  • 隆盛と衰退
  • 一貫型機会マップ

第10章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI4691

Global Acute Kidney Injury Treatment Market is estimated to be valued at USD 1.96 Bn in 2025 and is expected to reach USD 3.43 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.96 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.30% 2032 Value Projection: USD 3.43 Bn
Figure. Acute Kidney Injury Treatment Market Share (%), By Region 2025
Acute Kidney Injury Treatment Market - IMG1

Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.

Market Dynamics:

Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.

Key features of the study:

This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acute kidney injury treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market

Detailed Segmentation-

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Prerenal Acute Kidney Injury
    • Intrinsic Renal Acute Kidney Injury
    • Postrenal Acute Kidney Injury
  • Treatment Insights (Revenue, USD Bn, 2020 - 2032)
    • Therapy
    • Drugs
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Angion Biomedica Corp.
    • AM-Pharma
    • Quark Pharmaceuticals, Inc.
    • Baxter International, Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Braun Melsungen AG
    • Asahi Kasei Medical Co., Ltd.
    • LG Chem
    • Kringle Pharma, Inc.
    • AstraZeneca
    • Amgen Inc.
    • Gilead Sciences
    • Roche
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Novartis AG
    • AbbVie Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Acute Kidney Injury Treatment Market, By Type
    • Global Acute Kidney Injury Treatment Market, By Treatment
    • Global Acute Kidney Injury Treatment Market, By Distribution Channel
    • Global Acute Kidney Injury Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Acute Kidney Injury Treatment Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Prerenal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intrinsic Renal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Postrenal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Acute Kidney Injury Treatment Market, By Treatment, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Acute Kidney Injury Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Acute Kidney Injury Treatment Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Angion Biomedica Corp.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AM-Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Quark Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Baxter International, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fresenius Medical Care AG & Co. KGaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Braun Melsungen AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Asahi Kasei Medical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • LG Chem
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kringle Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG
  • AbbVie Inc.

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us